All Photos(1)



Mycophenolic acid

analytical standard

6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid, 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid, NSC 129185
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
EC Number:
MDL number:
PubChem Substance ID:

Quality Level


analytical standard


≥98.5% (HPLC)

shelf life

limited shelf life, expiry date on the label


HPLC: suitable
gas chromatography (GC): suitable


≤1.0% water


forensics and toxicology
pharmaceutical (small molecule)



storage temp.


SMILES string




InChI key


Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Mycophenolic acid is an active metabolite of the ester prodrug mycophenolate mofetil (MPM), which is prescribed as an immunosuppressant to prevent the organ transplantation rejection and also in the treatment of certain autoimmune diseases.


Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Mycophenolic acid (MPA), produced by Penicillum brevi-compactum, is a selective inhibitor of inosine monphosphate dehydrogenase, thus inhibiting DNA synthesis in T and B lymphocytes. It has also been shown to act as an immunosuppressive agent, and as an inducer of monocyte differentiation and apoptosis in human lymphoid and monocytic cell lines. As a selection agent, MPA is used for transfected animal cells expressing the E. Coli gene for xanthine-guanine phosphoribosyl transferase, and is recommended for use at 25μg/mL.
Mycophenolic acid may be used as a reference standard for the determination of the analyte in human plasma by ultra-performance liquid chromatography tandem mass spectrometry.

Biochem/physiol Actions

Mode of Action: This product acts by suppressing the cytokine-induced nitric oxide production, inhibiting early stage biosynthesis of purine nucleotides and as a specific inhibitor of IMP dehydrogenase.


As supplied, this product should be stored desiccated at 2-8°C, and is stable for 5 years when stored properly.

Preparation Note

Mycophenolic acid is soluble in methanol at 50 mg/mL, yielding a colorless to faint yellow solution, as well as chloroform, dichloromethane, ethanol and .1 N NaOH. After reconstitution, the recommendation is to sterilize via filtration thorugh a 0.22 μm pore-size filter, aliquot, and freeze at -20°C.

Signal Word


Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Muta. 2 - Repr. 1B - STOT RE 1 Oral

Target Organs

Immune system

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Origin

Enter Lot Number to search for Certificate of Origin (COO).

More documents

Quotes and Ordering

Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry.
Upadhyay V, et al.
Journal of Pharmaceutical Analysis, 4(3), 205- 216 (2014)
LC- MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum.
Merrigan SD, et al.
Clinical mass spectrometry, 3, 41- 48 (2017)
Use of mycophenolic acid in non-transplant renal diseases.
Patricia M Stassen et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(4), 1013-1019 (2007-02-20)
Burkhard Tönshoff et al.
Transplantation reviews (Orlando, Fla.), 25(2), 78-89 (2011-04-02)
Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppressive therapy in pediatric renal and heart transplant recipients. Children undergo developmental changes (ontogeny) of drug disposition, which may affect drug metabolism of the active compound mycophenolic acid (MPA). Therefore, a detailed
Hylke de Jonge et al.
Therapeutic drug monitoring, 31(4), 416-435 (2009-06-19)
Although therapeutic drug monitoring (TDM) of immunosuppressive drugs has been an integral part of routine clinical practice in solid organ transplantation for many years, ongoing research in the field of immunosuppressive drug metabolism, pharmacokinetics, pharmacogenetics, pharmacodynamics, and clinical TDM keeps

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service